URL has been copied successfully!
There must be some mistake. A company studies its cancer blood test in a randomized trial of 140,000 people using a suboptimal surrogate endpoint, fails to meet that endpoint, yet is recommended for approval by a Food and Drug Administration advisory panel. And because of the Medicare Multi-Cancer Early Detection Screening Coverage Act passed earlier this year, the company appears to be on track to have taxpayers foot the bill.
How does this happen?
Please follow us:
